NHS and the hydra of cancer drugs prices

We share the January 13th 2015 editorial from The Independent regarding the high cost of some cancer drugs and criticizing,rightfully,the steps taken by the UK government not to heed to NICE advice analysis before adding new drugs to the publicly funded list. A rise in pharmaceutical costs which has more to do with pharma companies pricing and business strategies than actual therapeutic impact and is affecting most European countries. En la web de la No Gracias podeis encontrar tanto el editorial como otros materiales relacionados debidamente traducidos y analizados. As usual we have added some hyperlinks and provided further information on the issue from the blog, our twitter feed and elsewhere 

Picture from Insurers seek lower drug prices, forcing Big Pharma to swallow a jagged little pill The Guardian Jan. 15th 2015

Unhappy pills
Manufacturers of cancer drugs cannot expect to keep charging more for them without paying a price themselves
With a limited budget, the NHS cannot meet every demand – and new demands keep arising. As accident and emergency departments face unprecedented pressures, despite the relatively mild winter and an emergency cash injection from the Government, they suck resources from other parts of the service which, sooner or later, feel the squeeze. This week it is the turn of the cancer services.